Ponsegromab

Synonyms: PF 06946860
Ponsegromab 是一种生长分化因子 15 (GDF15) 抑制剂,对人、食蟹猴和小鼠靶点的 IC50 值分别为 0.123 nM、0.053 nM 和 0.102 nM,可作为化学增敏剂增加细胞内活性氧水平并降低谷胱甘肽含量,可用于奥沙利铂耐药性结直肠癌的相关研究。
产品编号: MS-S51319 纯度: 99.60% CAS No.: 2368950-15-4
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Ponsegromab 是一种生长分化因子 15 (GDF15) 抑制剂,对人、食蟹猴和小鼠靶点的 IC50 值分别为 0.123 nM、0.053 nM 和 0.102 nM,可作为化学增敏剂增加细胞内活性氧水平并降低谷胱甘肽含量,可用于奥沙利铂耐药性结直肠癌的相关研究。

生物实验数据

生物活性 Ponsegromab is a growth differentiation factor 15 (GDF15) inhibitor with IC50 values of 0.123 nM, 0.053 nM, and 0.102 nM for the human, cynomolgus monkey, and mouse targets, respectively; it acts as a chemosensitizer to increase intracellular reactive oxygen species levels and decrease glutathione content, and can be used in research related to oxaliplatin-resistant colorectal cancer.
IC50 & Target GDF15-GFRAL:0.5037 μg/mL, GDF15:0.1095 μg/mL (EC50)
体外研究
(In Vitro)

Ponsegromab (log concentrations from -4 to 2 nM; 1 h at 37 °C) 在无细胞 ELISA 实验中可强效抑制人、食蟹猴和小鼠 GDF15 与 GFRAL 的结合,对应的 IC50值分别为 0.123 nM、0.053 nM 和 0.102 nM。
Ponsegromab (对数浓度范围为-4 至 1 nM;37℃、5% CO2条件下处理 17 h) 可强效抑制 HEK293 细胞中 GDF15-GFRAL-RET 介导的 ELK1 报告基因活性,其 IC50为 0.037 nM。
Ponsegromab (log 浓度范围为-4 至 2 nM) 可强效抑制 HEK293 细胞中 GDF15-GFRAL-RET 介导的 ERK1/2 磷酸化,其 IC50值为 0.051 nM。
Ponsegromab (对数浓度范围为-3 至 2 nM) 可强效抑制 HEK293 细胞中 GDF15-GFRAL-RET 介导的 AKT 磷酸化,其 IC50为 0.171 nM。
Ponsegromab (10 µg/mL; 48 h) 可使奥沙利铂耐药的结直肠癌细胞 LoVo-OxR 和 HCT-116-OxR 对奥沙利铂增敏,将其奥沙利铂 IC50值分别降至 8.176 μM 和 7.818 μM。
Ponsegromab (10 µg/mL; 48 h) 可增加经奥沙利铂处理的耐奥沙利铂结直肠癌细胞系 LoVo-OxR 和 HCT-116-OxR 中的细胞凋亡水平。
Ponsegromab (10 µg/mL; 48 h) 可调控奥沙利铂耐药结直肠癌细胞株 LoVo-OxR 和 HCT-116-OxR (经奥沙利铂处理) 中凋亡相关蛋白的表达,降低 Bcl-2 水平并升高活化的 caspase-3 (cleaved caspase-3) 水平。
Ponsegromab (10 µg/mL; 48 h) 可提高奥沙利铂耐药的结直肠癌细胞系 LoVo-OxR 和 HCT-116-OxR 中奥沙利铂诱导的细胞内 ROS 水平。
Ponsegromab (10 µg/mL; 48 h) 可降低经奥沙利铂处理的奥沙利铂耐药结直肠癌细胞株 LoVo-OxR 和 HCT-116-OxR 中的 GSH 水平及 GSSG/GSH 比值。
Ponsegromab (10 µg/mL; 48 h) 可降低奥沙利铂耐药性结直肠癌细胞株 LoVo-OxR 和 HCT-116-OxR 中Nrf2、NQO1及HO-1的蛋白表达水平。
Ponsegromab (10 µg/mL; 48 h) 可在奥沙利铂耐药的结直肠癌细胞系 LoVo-OxR 和 HCT-116-OxR 中增强 Nrf2 的多泛素化修饰,并减少 Nrf2 与 β-TrCP 的相互作用。
Ponsegromab (10 µg/mL; 48 h) 可提高耐奥沙利铂的结直肠癌细胞 HCT-116-OxR 中Nrf2蛋白的降解速率。
Ponsegromab (10 µg/mL; 2 h) 可通过泛素-蛋白酶体通路降低耐奥沙利铂的结直肠癌细胞 LoVo-OxR 和 HCT-116-OxR 中的Nrf2蛋白水平,而 MG132 处理可恢复 Nrf2的表达。

Cell Viability Assay

Cell Line: LoVo-OxR, HCT-116-OxR (oxaliplatin-resistant human colorectal cancer cell lines)
Concentration: 10 µg/mL (in combination with oxaliplatin at 0, 2, 4, 8, 16, 32 μM)
Incubation Time: 48 h
Result: Reduced the half-maximal inhibitory concentration (IC50) of oxaliplatin in LoVo-OxR cells from 14.290 μM to 8.176 μM, and in HCT-116-OxR cells from 19.650 μM to 7.818 μM, sensitizing the resistant cell lines to oxaliplatin treatment.

Apoptosis Analysis

Cell Line: LoVo-OxR, HCT-116-OxR (oxaliplatin-resistant human colorectal cancer cell lines)
Concentration: 10 µg/mL (in combination with 14.29 μM oxaliplatin for LoVo-OxR, 19.65 μM oxaliplatin for HCT-116-OxR)
Incubation Time: 48 h
Result: Increased the proportion of apoptotic cells in oxaliplatin-treated LoVo-OxR and HCT-116-OxR cells, compared to oxaliplatin treatment alone.

Western Blot Analysis

Cell Line: LoVo-OxR, HCT-116-OxR (oxaliplatin-resistant human colorectal cancer cell lines)
Concentration: 10 µg/mL (in combination with 14.29 μM oxaliplatin for LoVo-OxR, 19.65 μM oxaliplatin for HCT-116-OxR)
Incubation Time: 48 h
Result: Reduced anti-apoptotic Bcl-2 protein levels and increased pro-apoptotic cleaved caspase-3 protein levels in oxaliplatin-treated LoVo-OxR and HCT-116-OxR cells.

Western Blot Analysis

Cell Line: LoVo-OxR, HCT-116-OxR (oxaliplatin-resistant human colorectal cancer cell lines)
Concentration: 10 µg/mL
Incubation Time: 48 h
Result: Reduced protein levels of Nrf2, as well as its downstream antioxidant target genes NQO1 and HO-1, in LoVo-OxR and HCT-116-OxR cells.\nIncreased polyubiquitination of Nrf2 and impaired the interaction between Nrf2 and β-TrCP (a ubiquitin ligase adapter) in LoVo-OxR and HCT-116-OxR cells.

Western Blot Analysis

Cell Line: HCT-116-OxR (oxaliplatin-resistant human colorectal cancer cell line)
Concentration: 10 µg/mL
Incubation Time: 48 h (prior to cycloheximide chase over 60 min)
Result: Increased the rate of Nrf2 protein degradation in HCT-116-OxR cells, reducing the half-life of Nrf2 protein compared to untreated control cells.

Western Blot Analysis

Cell Line: LoVo-OxR, HCT-116-OxR (oxaliplatin-resistant human colorectal cancer cell lines)
Concentration: 10 µg/mL (in combination with 10 μM MG132)
Incubation Time: 2 h
Result: Reduced Nrf2 protein levels in LoVo-OxR and HCT-116-OxR cells, and this inhibitory effect was reversed by MG132 treatment, restoring Nrf2 expression.
体内研究
(In Vivo)

Ponsegromab (10 mg/kg; i.p.; twice weekly; until study endpoint) 可在罹患癌症恶病质的 HT-1080 荷瘤 NCG 小鼠中提升腓肠肌及附睾脂肪的重量。
Ponsegromab (10 mg/kg; i.p.; once every 3 days; until study endpoint) 可在罹患癌症恶病质的 HT-1080 荷瘤 NCG 小鼠中恢复体重、增加自主活动量、使呼吸交换比部分恢复正常,并提升产热。
Ponsegromab (10 mg/kg; i.p.; twice weekly; until study endpoint) 可部分逆转罹患癌症恶病质的 Renca 荷瘤 BALB/c 小鼠的体重下降。
Ponsegromab (10 mg/kg; i.p.; twice weekly; until study endpoint) 可部分逆转患有癌症恶病质的 MC38-hGDF15 荷瘤 C57BL/6 小鼠的体重下降。
Ponsegromab (10 mg/kg; i.p.; once every 3 days; day 6 to day 21) 可在接受顺铂治疗的化疗诱导恶病质 C57BL/6 小鼠中维持体重、实现 100% 存活率、恢复腓肠肌重量,并部分恢复附睾脂肪重量。

Animal Model: NCG mice (6-week-old male; cancer cachexia model via subcutaneous HT-1080 human fibrosarcoma cell inoculation)
Dosage: 10 mg/kg
Administration: i.p.; twice weekly; until study endpoint
Result: Increased gastrocnemius muscle weight; significantly increased epididymal fat weight compared to vehicle control.
Animal Model: NCG mice (6-week-old male; cancer cachexia model via subcutaneous HT-1080 human fibrosarcoma cell inoculation)
Dosage: 10 mg/kg
Administration: i.p.; once every 3 days; until study endpoint
Result: Restored lost body weight in cachectic mice; increased ambulatory activity compared to vehicle control; partially restored respiratory exchange ratio towards non-tumor bearing levels; increased heat production compared to vehicle control.
Animal Model: BALB/c mice (6-week-old male; cancer cachexia model via subcutaneous Renca murine kidney tumor cell inoculation)
Dosage: 10 mg/kg
Administration: i.p.; twice weekly; until study endpoint
Result: Led to partial recovery of body weight in cachectic mice, though body weight did not return to non-tumor bearing levels.
Animal Model: C57BL/6 mice (6-week-old male; cancer cachexia model via subcutaneous MC38-hGDF15 murine colon cancer cell inoculation overexpressing human GDF15)
Dosage: 10 mg/kg
Administration: i.p.; twice weekly; until study endpoint
Result: Led to partial recovery of body weight in cachectic mice, though body weight did not return to non-tumor bearing levels.
Animal Model: C57BL/6 mice (6-week-old male; chemotherapy-induced cachexia model via cisplatin injection)
Dosage: 10 mg/kg
Administration: i.p.; once every 3 days; day 6 to day 21
Result: Maintained body weight in cachectic mice (preventing continued weight loss seen in vehicle and isotype control groups), with endpoint body weight similar to normal untreated mice; achieved 100% survival to study endpoint; restored gastrocnemius muscle weight to normal levels; partially restored epididymal fat weight compared to vehicle control.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT03599063Pfizer
Healthy
2018-07-30PHASE1
NCT03974776Pfizer
Healthy
2019-07-08PHASE1
NCT04299048Pfizer
Cachexia|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Colorectal Cancer
2020-11-17PHASE1
性状 液体
颜色 Colorless to light yellow

化学信息

CAS No. 2368950-15-4
别名 PF 06946860

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础